Clearside Biomedical Inc

NASDAQ:CLSD  
2.24
+0.01 (+0.45%)
Products, Regulatory

Clearside Biomedical Inc Announces Positive Safety Results From Oasis Phase 1/2A Clinical Trial Of Cls-Ax (Axitinib Injectable Suspension) For The Treatment Of Wet AMD

Published: 12/21/2021 12:23 GMT
Clearside Biomedical Inc (CLSD) - Clearside Biomedical Announces Positive Safety Results From Oasis Phase 1/2a Clinical Trial of Cls-ax (axitinib Injectable Suspension) for the Treatment of Wet Amd.
Clearside Biomedical Inc - Suprachoroidal Injection of Cls-ax 0.1 Mg Dose Well-tolerated in Cohort 2 With No Treatment Related Adverse Events.
Clearside Biomedical - Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to Cohort 3.
Clearside Biomedical Inc - Oasis Safety Monitoring Committee Has Reviewed Data and Approved Advancing to Cohort 3 With a Dose of 0.5 Mg of Cls-ax.
Clearside Biomedical Inc - Have Initiated Patient Screening for Cohort 3, With Target Completion of This Cohort Planned for Mid-year 2022.
Clearside Biomedical Inc - Primary Endpoints Were Achieved in Cohort 2.